TransPharMed

What TransPharMed does

TransPharMed (legal entity: TransPharMed Commercialization Lab) is a private digital health commercialization standards body founded in 2017 and headquartered at 2870 Peachtree Road, Suite 1568, Atlanta, Georgia. The company has codified its offering into the PROS Commercial Architecture, a four-pillar framework comprising PREP (Professional Readiness, delivered via the Digital Health Sales Institute certification), REV (Revenue Diagnostics, delivered through the CRA, CETA, and CEFA audit suite producing a standardized Commercial Health Score), OPS (Operating Standards, delivered through the Commercial Minimum Viable Stack or CMVS, which defines stage-appropriate infrastructure for CRM, staging, AI workflows, and economic modeling across Seed, Series A, and Series B+ stages), and SIGNALS (Commercial Intelligence, delivered through the Commercial Signals Lab platform launching Q4 2026). The REV Audit Suite is launching in Q2 2026.

The company targets five customer segments: sales professionals seeking digital health fluency (via DHSI certification), startup founders needing commercial readiness assessment before hiring sales, VCs and accelerators seeking portfolio commercialization diligence, corporations and health systems upskilling sales teams and setting vendor intake standards, and governments and trade missions measuring export readiness. Revenue is generated through a mix of professional services (audit fees, CMVS assessments) and subscription/recurring models (DHSI certification, forthcoming Signals Lab subscriptions); pricing is not publicly disclosed and is quote-based via inquiry forms. The go-to-market is enterprise field sales complemented by a community-led motion (DHSI) and event/content-driven engagement (the SigCom newsletter as a public dispatch from the Signals Lab).

Operationally, TransPharMed runs with 1–10 employees, has no disclosed funding rounds, no disclosed revenue, and no disclosed partnerships. The leadership data available identifies Kirk Barnes as co-founder; the website's testimonial section references Tim Rice as a customer/founder who raised a $5MM seed round, not as TransPharMed's CEO. AI is deployed as a process-automation layer within CMVS (pre-call stakeholder briefs, post-call follow-up, structured handoffs) rather than as a core differentiator. The company explicitly positions itself as the neutral authority defining "commercially ready" in digital health, drawing an analogy to Rock Health for funding intelligence and PHTI for clinical efficacy.

Name

TransPharMed

Legal name

TransPharMed Commercialization Lab

Website

https://transpharmed.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

TransPharMed is a private Atlanta-based digital health commercialization standards body that sells the PROS framework — DHSI certification, REV audits, CMVS operating standards, and the forthcoming Signals Lab — to sales professionals, startup founders, VCs, corporates, and governments.

Ownership category

akta.pro rank

Product category

Digital Health Commercialization Services

NAICS

Professional, Scientific, and Technical Services (541)

akta.pro primary industry

Healthcare Licensing, Accreditation & Credentialing Boards (HLAJACAC)

Keywords

• Digital health consulting
• Commercial diagnostics
• Sales certification
• Commercialization standards
• Healthcare go-to-market

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. DHSI Certification: Professional certification for digital health commercial mastery - the world's first professional certification for digital health sales. Revenue generated through certification fees for sales professionals.
2. Revenue Audit Suite (REV): Three commercial performance diagnostics (CRA, CETA, CEFA) providing objective commercial readiness assessments. Revenue from audit service fees for founders, VCs, accelerators, and enterprise partners.
3. CMVS Standards Assessment: Stage-appropriate infrastructure assessments and benchmarking for digital health companies at Seed, Series A, and Series B+ stages.
4. Commercial Intelligence (Signals): Intelligence platform providing structured commercialization data for VCs, accelerators, enterprise innovation teams, and governments - launching Q4 2026.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels4 records

Core offering

TransPharMed Commercialization Lab operates as a commercial standards body for digital health, delivering the PROS Commercial Architecture (Prep → Rev → Ops → Signals). It sells professional certification through the Digital Health Sales Institute, commercial performance diagnostics through the REV Audit Suite (CRA, CETA, CEFA audits producing a Commercial Health Score), stage-appropriate infrastructure standards via CMVS, and an upcoming Commercial Signals Lab intelligence platform. Customers are digital health sales professionals, startup founders, VCs/accelerators, and corporations/health systems.

Product overview

TransPharMed Commercialization Lab operates as a platform-plus-modules architecture centered on the PROS Commercial Architecture (Prep → Rev → Ops → Signals). The core offerings include: DHSI (Digital Health Sales Institute) for professional certification and training; the REV Audit Suite for commercial diagnostics with three specialized audits (CRA, CETA, CEFA) producing Commercial Health Scores; CMVS Standards for stage-appropriate infrastructure and AI automation workflows; and the Commercial Signals Lab for market intelligence and benchmarking. The platform serves sales professionals, startup founders, VCs/accelerators, and corporations/health systems with standardized commercialization readiness tools.

Differentiator

Problem solved

Functional benefit

Brands

• PROS Commercial Architecture: A systematic approach to digital health commercialization comprising PREP (Professional Readiness), REV (Revenue Diagnostics), OPS (Operating Standards/CMVS), and SIGNALS (Commercial Intelligence).
• Digital Health Sales Institute (DHSI)
• Revenue Audit Suite (REV)
• Commercial Minimum Viable Stack (CMVS)
• Commercial Signals Lab (SIGNALS)

Products and services

• Digital Health Sales Institute (DHSI) Certification The world's first professional certification program for digital health commercial mastery, enabling sales professionals and enterprise sales teams to master consensus selling, economic translation, and enterprise trust in digital health buyer environments. Offered as a core DHSI Certification track and a DHSI Corporate Track for enterprise sales teams.
• REV Audit Suite (Revenue Audit Suite) Three specialized commercial performance diagnostics producing a standardized Commercial Health Score: CRA (Commercial Readiness Audit) for sales hiring readiness, CETA (Clinical-Economic Translation Audit) for enterprise budget validation, and CEFA (Commercial Execution Friction Audit) for pilot/enterprise deal diagnostics. Sold to startup founders, VCs, accelerators, and enterprise innovation teams.
• CMVS Standards (Commercial Minimum Viable Stack) Commercial Minimum Viable Stack defines stage-appropriate infrastructure standards (Seed, Series A, Series B+) covering CRM, staging methodology, sales vaults, AI workflows, and economic modeling to systematize digital health commercialization for early-stage companies.
• Commercial Signals Lab

Quantifiable outcome

• Mis-hires costing $250K-500K per failed rep can be prevented with CRA assessment
• +1 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• HIMSS: Global non-profit health IT membership organization that sets industry standards (e.g., HIMSS Analytics maturity models), runs certification programs, and convenes the digital health ecosystem. The established incumbent standards body for health IT — comparable in scope and ambition, though operating from a far larger institutional base.

Direct peers

• Pavilion: Membership-based community and training platform for B2B sales and revenue leaders offering certification, peer learning, and best-practice content. Closely comparable to DHSI's role as a sales-mastery certification — both monetize professional certification and community for go-to-market leaders.
• Force Management: B2B sales effectiveness consultancy selling a proprietary sales methodology (Force Management Framework) with certification, training, and customer-success services. Comparable to TransPharMed's DHSI and CMVS offerings — both monetize structured sales methodologies with certification and enablement components.
• Galen Growth: Digital health market intelligence and analytics firm producing proprietary research on company performance, funding, and commercialization outcomes. Closely comparable to TransPharMed's Commercial Signals Lab product line — both monetize proprietary digital health commercial datasets for investors and enterprises.
• Sales Assembly: Training, community, and certification platform for B2B SaaS sales professionals with structured learning paths and career development programs. Directly comparable to DHSI's positioning as a sales-mastery certification — both target individual sales professionals seeking credentials to advance in technology sales.
• Rock Health: Digital health venture fund and industry intelligence organization that publishes funding data, sector research, and ecosystem analysis. TransPharMed explicitly invokes Rock Health as the analog for its own 'funding intelligence' role in digital health commercialization — both occupy standards/information-body positions in the same ecosystem.
• Peterson Health Technology Institute (PHTI): Independent non-profit that evaluates digital health technologies on clinical efficacy and economic impact, producing standardized assessment reports for payers and providers. TransPharMed explicitly cites PHTI as the analog for its clinical-efficacy role — PHTI occupies the equivalent authority position on the clinical dimension that TransPharMed seeks on the commercial dimension.

Emerging players

• Health Evolution: Digital health executive community convening CEOs, payers, providers, and innovators through curated forums and research. Comparable to TransPharMed's DHSI community-building approach and shared audience of digital health buyers, investors, and operators.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/transpharmed
• LinkedInlinkedin.com/company/transpharmed

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TransPharMed